Synapse - Nivetha Ganesan

Results (54)

Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: A prospective geriatric assessment (GA) study

Meeting Abstract

Torka, P.; Drill, E.; Ganesan, N.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
Blood (2023)

Fulltext@MSK | Save

Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK/STAT-dependent inflammatory cascades

Meeting Abstract

Moskowitz, A.; Rahman, J.; Ganesan, N.; Hannigan, K.; Ksanznak, K.; Bitton, H.; Lin, Y. H.; Davey, T.; Hancock, H.; Perez, L.; more...
Blood (2023)

Fulltext@MSK | Save

Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma

Meeting Abstract

Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
Blood (2023)

Fulltext@MSK | Save

TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence

Journal Article

Wu, G.; Yoshida, N.; Liu, J.; Zhang, X.; Xiong, Y.; Heavican-Foral, T. B.; Mandato, E.; Liu, H.; Nelson, G. M.; Yang, L.; more...
Science Translational Medicine (2023)

Fulltext@MSK | Save

TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy

Journal Article

Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; more...
Blood Advances (2023)

Fulltext@MSK | Save

PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma

Meeting Abstract

Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma

Meeting Abstract

Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Arsenic-contaminated drinking water and cholangiocarcinoma

Journal Article

Reyes, D.; Ganesan, N.; Boffetta, P.; Labgaa, I.
European Journal of Cancer Prevention (2023)

Fulltext@MSK | Save

Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
Blood (2022)

Fulltext@MSK | Save

Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: Characterization of a large cohort with long-term outcomes shows disparate outcomes by body region involvement

Meeting Abstract

Stuver, R.; Ghione, P.; Ganesan, N.; Noor, S.; Imber, B. S.; Pulitzer, M.; Horwitz, S. M.
Blood (2022)

Fulltext@MSK | Save